RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research

Translational Stroke Research

Volumn 4, Issue 3, 2013, Pages 279-285

  Lapchak, Paul A ^a   Zhang, John H ^b   Noble Haeusslein, Linda J ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Clinical Trial; Hemorrhage; ICH; NIHSS; RIGOR; SAH; STAIR; STEPS; Stroke; Translational

Indexed keywords

ACCURACY; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFLICT OF INTEREST; MEDICAL HISTORY; MEDICAL RESEARCH; METHODOLOGY; POWER ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; REPRODUCIBILITY; STATISTICAL ANALYSIS;

BRAIN; CLINICAL TRIAL; HEMORRHAGE; ICH; NIHSS; RIGOR; SAH; STAIR; STEPS; STROKE; TRANSLATIONAL;

AGED; CLINICAL LABORATORY TECHNIQUES; DISCLOSURE; FEMALE; HISTORY, 16TH CENTURY; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; STEM CELL TRANSPLANTATION; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84877134982     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0209-2     Document Type: Article

References (53)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121(7): e46-e215.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010; 121(7): 948-54.
3. Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4. 5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2012. doi: 10. 1016/j. annemergmed. 2012. 04. 020.
4. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317-29.
5. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4. 5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009; 40(7): 2438-41.
6. group ISTc, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(9834): 2352-63. Multicenter Study Randomized Controlled Trial Research Support, Non-U. S. Gov't.
7. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010; 5(7): 406-9.
8. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995; 333(24): 1581-7.
9. Poirier J, Derouesné D. VIII. 9: apoplexy and stroke. The cambridge world history of human disease. 1993. doi: 10. 1017/CHOL9780521332866. 071.
10. Wepfer JJ. Observationes anatomicae ex cadaveribus eorum, quos sustulit apoplexia cum exercitatione de eius loco affecto. Schaffhausen, Switzerland: O. A. Waldkirch; 1675.
11. Gurdjian ES, Gurdjian ES. History of occlusive cerebrovascular disease I. from Wepfer to Moniz. Arch Neurol. 1979; 36(6): 340-3. Historical Article.
12. Willis T. Cerebri Anatome: cui accessit nervorum descriptio et usus. London; 1664.
13. Dechambre A. Dictionnaire Encyclopédique des Sciences Médicales. Paris, France; 1866; 18.
14. Virchow R. Thrombose und Embolie: Gefässenzýndung und Septische Infektion, in Gesammelte Abhandlungen zur wissen schaftlichen Medicin. Frankfurt: a. M., Meidinger, Sohn und Co; 1856.
15. Bramwell B. Spontaneous meningeal haemorrhage. Edinb Med J. 1886; 32: 101.
16. Symonds CP. Spontaneous sub-arachnoid haemorrhage. Proc Royal Soc Med. 1924; 17: 39-52. Neurol Sect.
17. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009; 119(3): 480-6.
18. Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002; 2(1): 38-43.
19. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993; 5(1): 1-16.
20. Bernstein RA, Del-Signore M. Recent advances in the management of acute intracerebral hemorrhage. Curr Neurol Neurosci Rep. 2005; 5(6): 483-7.
21. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007; 369(9558): 306-18.
22. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010; 1(2): 96-107. Perspective Review.
23. Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl Stroke Res. 2011; 2(2): 129-35.
24. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009; 40(3 Suppl): S111-4.
25. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010; 67(2): 181-98.
26. Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs. 2011; 20(1): 13-22.
27. Chen J, Chopp M. Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx. 2006; 3(4): 466-73.
28. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999; 30(12): 2752-8.
29. Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl Stroke Res. 2011; 2(2): 138-43.
30. Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012; 9(2): 371-9.
31. Fisher M. Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke. 2003; 34(6): 1539-46.
32. Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007; 38(2): 245-8.
33. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009; 40(7): 2594-600. Congresses Research Support, N. I. H., Extramural.
34. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011; 42(9): 2645-50. Practice Guideline Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't.
35. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357(6): 562-71.
36. Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009; 157(7): 1157-71.
37. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008; 28(1): 217-9.
38. Ginsberg MD. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke. 2007; 38(6): 1967-72.
39. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007; 205(1): 20-5.
40. Savitz SI. Cosmic implications of NXY-059. Stroke. 2009; 40(3 Suppl): S115-8.
41. Pardo Cabello AJ, Bermudo Conde S, Manzano Gamero V, Gomez Jimenez FJ, de la Higuera Torres-Puchol J. Implementation of clinical practice guidelines for acute ischaemic stroke in specialist care centres. Neurologia. 2012. doi: 10. 1016/j. nrl. 2012. 04. 008.
42. Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke. 2012; 43(2): 432-40.
43. Kiers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC, et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry. 1992; 55(4): 263-70. Research Support, Non-U. S. Gov't.
44. Baird TA, Parsons MW, Barber PA, Butcher KS, Desmond PM, Tress BM, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci. 2002; 9(6): 618-26. Research Support, Non-U. S. Gov't Review.
45. Lees KR, Walters MR. Acute stroke and diabetes. Cerebrovasc Dis. 2005; 20 Suppl 1: 9-14. Review.
46. Wechsler L, Steindler D, Borlongan C, Chopp M, Savitz S, Deans R, et al. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009; 40(2): 510-5. Review.
47. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke. 2011; 42(3): 825-9. Congresses.
48. RIGOR. Improving the quality of NINDS-supported preclinical and Clinical Research through rigorous study design and transparent reporting. 2012; Available from: http://www. ninds. nih. gov/funding/transparency_in_reporting_guidance. pdf.
49. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, National Centre for the Replacement R, et al. Animal research: reporting in vivo experiments-the ARRIVE guidelines. J Cereb Blood Flow Metab. 2011; 31(4): 991-3. Research Support, Non-U. S. Gov't.
50. Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One. 2009; 4(11): e7824. Research Support, Non-U. S. Gov't.
51. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007; 38(12): 3205-12.
52. Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the national institutes of health stroke scale: results of a factor analysis. Stroke. 1999; 30: 2347.
53. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 2006; 5(7): 603-12.